Novo Nordisk cut its 2025 guidance and outgoing CEO blames the compounding market for it.
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
July 29, 2025
You may also like
Indices by TradingView
Is Robinhood Stock a Millionaire Maker?
January 19, 2026
What Does the Street Think About Broadcom Inc. (AVGO)?
January 19, 2026
3 Stocks to Buy for 2026 That Are Practically Money Machines
January 19, 2026
Dow Jones Futures Fall Over Trump Greenland Tariffs On NATO Nations
January 18, 2026
3 Top Quantum Computing Stocks to Buy in 2026
January 18, 2026
Categories
Indices by TradingView


